#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

News

MOZOG NEURON

Ocrelizumab in the Treatment of Multiple Sclerosis –⁠ 10-Year Data

20. 2. 2024 Source: Neurology - Multiple Sclerosis

Multiple sclerosis (MS) is a lifelong disease with a high risk of permanent disability. Current information on the long-term efficacy and safety of treatment is therefore absolutely essential for the optimal choice of therapeutic agent –⁠ in this case, ocrelizumab.

symptomatická léčba

Long-term Efficacy and Safety of Mavacamten in the Treatment of Obstructive HCM

Interim results of the MAVA-LTE study provide the latest data on the long-term safety and efficacy…
19. 2. 2024 Source: Hypertrophic Cardiomyopathy (HCM)
farmakoterapie

Mavacamten in the Treatment of HCM in Patients Referred for Septal Reduction

Extended 56-week follow-up of patients with hypertrophic cardiomyopathy (HCM) resistant to current…
19. 2. 2024 Source: Hypertrophic Cardiomyopathy (HCM)
starší muž aktivita

How Does Myelodysplastic Syndrome Affect Patients' Quality of Life?

Myelodysplastic syndrome (MDS) is a heterogeneous group of disorders of hematopoietic stem cells…
15. 2. 2024 Source: Myelodysplastic Syndrome (MDS)
3D tisk

Planning Surgery Using 3D Printing in Practice –⁠ Case Study

In October 2023, an article by neurosurgeons from Leipzig University was published in the journal …
25. 1. 2024 Source: medScope.pro
trombocyty

Immunomodulation and Romiplostim −⁠ What Does the Recently Published iROM Study Say?

Primary immune thrombocytopenia (ITP) is caused by an immunity disorder, involving not only the…
24. 1. 2024 Source: Immune Thrombocytopenia
klinickastudie

ICIS Report: Potential of TPO-RA as Early Immunomodulatory Treatment of Immune Thrombocytopenia

The report from the meeting of the Intercontinental Cooperative ITP Study Group (ICIS) in 2022 in…
24. 1. 2024 Source: Immune Thrombocytopenia
léčba leukemie_lékař a pacient

Impact of Azacitidine Maintenance Therapy on Survival of Patients with AML in Remission Depending on Initial Chemotherapy

The QUAZAR AML-001 study showed that oral azacitidine maintenance therapy significantly prolongs…
24. 1. 2024 Source: Acute Myeloid Leukemia
docSova

Doc. Milan Sova: AAT substitution is available to all indicated patients. It is therefore crucial to now educate about the necessity of regular treatment

Alpha-1-antitrypsin deficiency (AATD) is one of the most common genetic disorders in adults. It is…
18. 1. 2024 Source: Deficiency of Alpha-1-Antitrypsin
kost_

Anabolic Antiosteoporotic Treatment as a First Step in Patients with Very High Fracture Risk

According to the 2022 opinion of the ESCEO (European Society for Clinical and Economic Aspects of…
18. 1. 2024 Source: Osteoporosis – Trends in Sequential Therapy
1 21 22 23 24 25 169
Filter by speciality
Remove filters

Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#